- Home
- RVYL vs RNAZ Comparison
RVYL vs RNAZ Comparison
Compare RVYL & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVYL
- RNAZ
- Stock Information
- Founded
- RVYL 2007
- RNAZ 2016
- Country
- RVYL United States
- RNAZ United States
- Employees
- RVYL N/A
- RNAZ N/A
- Industry
- RVYL Professional Services
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- RVYL Consumer Discretionary
- RNAZ Health Care
- Exchange
- RVYL Nasdaq
- RNAZ Nasdaq
- Market Cap
- RVYL 8.2M
- RNAZ 281.3K
- IPO Year
- RVYL N/A
- RNAZ 2021
- Fundamental
- Price
- RVYL $0.86
- RNAZ $0.35
- Analyst Decision
- RVYL Hold
- RNAZ Strong Buy
- Analyst Count
- RVYL 1
- RNAZ 1
- Target Price
- RVYL N/A
- RNAZ $10.00
- AVG Volume (30 Days)
- RVYL 26.6K
- RNAZ 10.2M
- Earning Date
- RVYL 05-13-2025
- RNAZ 05-20-2025
- Dividend Yield
- RVYL N/A
- RNAZ N/A
- EPS Growth
- RVYL N/A
- RNAZ N/A
- EPS
- RVYL N/A
- RNAZ N/A
- Revenue
- RVYL $55,998,000.00
- RNAZ N/A
- Revenue This Year
- RVYL $36.61
- RNAZ N/A
- Revenue Next Year
- RVYL $26.67
- RNAZ N/A
- P/E Ratio
- RVYL N/A
- RNAZ N/A
- Revenue Growth
- RVYL N/A
- RNAZ N/A
- 52 Week Low
- RVYL $0.69
- RNAZ $0.22
- 52 Week High
- RVYL $2.40
- RNAZ $66.33
- Technical
- Relative Strength Index (RSI)
- RVYL 37.89
- RNAZ 34.92
- Support Level
- RVYL $0.87
- RNAZ $0.35
- Resistance Level
- RVYL $0.97
- RNAZ $0.79
- Average True Range (ATR)
- RVYL 0.07
- RNAZ 0.09
- MACD
- RVYL -0.01
- RNAZ 0.08
- Stochastic Oscillator
- RVYL 0.00
- RNAZ 14.82
About RVYL Ryvyl Inc.
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.